IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 171 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.14 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,024,750 | +343.1% | 445,000 | +584.6% | 0.68% | +390.6% |
Q2 2023 | $456,950 | +33.8% | 65,000 | +16.1% | 0.14% | +46.3% |
Q1 2023 | $341,600 | -4.4% | 56,000 | 0.0% | 0.10% | -13.6% |
Q4 2022 | $357,280 | -33.3% | 56,000 | 0.0% | 0.11% | -36.0% |
Q3 2022 | $536,000 | -99.8% | 56,000 | +1759.8% | 0.17% | -94.0% |
Q2 2022 | $273,000,000 | +9526.2% | 3,011 | -94.8% | 2.85% | +345.0% |
Q1 2022 | $2,836,000 | +156.4% | 58,000 | 0.0% | 0.64% | +160.2% |
Q4 2021 | $1,106,000 | -22.7% | 58,000 | 0.0% | 0.25% | -28.7% |
Q3 2021 | $1,430,000 | -5.2% | 58,000 | 0.0% | 0.34% | -13.3% |
Q2 2021 | $1,509,000 | -17.8% | 58,000 | 0.0% | 0.40% | -18.1% |
Q1 2021 | $1,836,000 | -31.8% | 58,000 | 0.0% | 0.49% | -33.9% |
Q4 2020 | $2,693,000 | -43.6% | 58,000 | -60.0% | 0.74% | -52.3% |
Q3 2020 | $4,773,000 | +87.7% | 145,000 | +39.4% | 1.54% | +63.4% |
Q2 2019 | $2,543,000 | – | 104,000 | – | 0.94% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ACUTA CAPITAL PARTNERS, LLC | 2,944,201 | $27,999,000 | 13.31% |
Broadfin Capital, LLC | 4,328,303 | $41,162,000 | 8.50% |
GREAT POINT PARTNERS LLC | 5,567,348 | $52,945,000 | 5.24% |
FRAZIER MANAGEMENT LLC | 2,188,331 | $20,811,000 | 5.01% |
Avoro Capital Advisors LLC | 10,530,862 | $100,148,000 | 4.33% |
Prosight Management, LP | 917,080 | $8,721,000 | 3.82% |
Perceptive Advisors | 12,235,811 | $116,362,000 | 3.28% |
Ghost Tree Capital, LLC | 1,150,000 | $10,937,000 | 2.86% |
QVT Financial LP | 1,021,361 | $9,241,000 | 2.32% |
Cheyne Capital Management (UK) LLP | 186,500 | $1,774,000 | 1.66% |